- Cannabis-based medicine supplier Althea (AGH) launches two new products to meet patient needs
- Althea CBD25 is the company’s exclusive range of soft gel capsules which contain less than 25mg of cannabidiol and less than 0.25mg of THC
- Subject to TGA schedule three entry for eligible CBD products, patients will be able to purchase the product over the counter
- Althea THC25 is an ultra-high THC cannabis dried flower and will be AGH’s highest-concentrated dried flower product that contains 25 per cent THC and less than one per cent CBD
- Shares in Althea are up 7.95 per cent on the market and are trading at 9.5 cents at 12:33 pm AEST
Cannabis-based medicine supplier Althea (AGH) has launched two new products, Althea CBD25 and Althea THC25, to meet patient needs.
Althea CBD25 is the company’s exclusive range of soft gel capsules which have been manufactured to EU-GMP standard.
Each capsule contains less than 25 milligrams (mg) of cannabidiol (CBD) and less than 0.25mg of delta-9-tetrahydrocannabinol (THC).
The capsules also contain terpenes, flavonoids and other phytochemicals which have synergistic effects.
The capsules are administered orally and offer a gradual onset and extended duration of effect compared to the rapid onset and shorter duration of inhaled products.
Subject to regulatory approvals, the Althea CBD25 capsules are a candidate to be supplied under the Therapeutic Goods Administration’s (TGA) schedule three entry for eligible CBD products.
This will allow patients to purchase the product over the counter after consultation with a pharmacist without needing a prescription.
Althea THC25 is an ultra-high THC cannabis dried flower product that was grown in a Canadian greenhouse to meet the rigid standards of a pharmaceutical inhalation product.
It contains 25 per cent THC and less than one per cent CBD and is rich in terpene and flavonoids.
Althea THC25 will be the company’s highest-concentrated THC dried flower product and will be available in Australia, Germany and the United Kingdom.
“The development and release of our new soft gel capsule range confirms Althea’s position as a market leader and product innovator in the global medical cannabis industry,” CEO and Managing Director Joshua Fegan commented.
“Launching at a very competitive price point globally, we believe Althea’s soft gel capsules will create incremental sales opportunities for the business, with market research clearly identifying this preparation as the most desirable choice of delivery format.
“The growth of the flower segment in Australia has been significant over the previous 12 months and as the undisputed market leader in cannabis extracts, it is strategically important for Althea to have strong market share in the flower category as well.”
Shares in Althea were up 7.95 per cent on the market and were trading at 9.5 cents at 12:33 pm AEST.